Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Prostate Cancer

Sex eligibility

Male

Study type

Observational

Primary location

Investigational site (there may be other sites in this country)

Rottweil, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)
Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment

Exclusion criteria

Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.
Participation in a clinical trial at baseline and during the follow-up period

Treatment and study plan

degarelix

Drug

According to medical practice

Other names: Firmagon®

LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)

Drug

According to medical practice

Primary outcomes

Level of urologist's knowledge of patients' medical history at the point of decision making and during Androgen Deprivation Therapy (ADT)

Time frame: Up to 4 years

Measured by questionnaires by quantifying the frequency of urologists' entries
Level of urologist's knowledge of patients' comorbidities at the point of decision making and during ADT

Time frame: Up to 4 years

Measured by questionnaires by quantifying the frequency of urologists' entries
Level of urologist's knowledge of patients' concomitant medications at the point of decision making and during ADT

Time frame: Up to 4 years

Measured by questionnaires by quantifying the frequency of urologists' entries
Level of urologist's knowledge of patients' risk factors at the point of decision making and during ADT

Time frame: Up to 4 years

Measured by questionnaires by quantifying the frequency of urologists' entries

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Acronym: ProComD

Important dates

Study start: 2014
Primary completion: 2019
Study completion: 2019
First posted: Sep 9, 2014
Registry last updated: Jul 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed